We define market access broadly, encompassing all steps necessary to make new treatments and technologies available to patients in the emerging market world.
This often involves looking at a therapeutic area in terms of policy, treatment guidelines, funding and infrastructure as well as securing regulatory approvals and reimbursement for products in private and public healthcare systems.
At the heart of our approach is an understanding of the 'politics of market access' i.e. that while decisions should be taken based on a combination of science and economics, the acute pressures on healthcare systems mean that political choices almost always come into play. Those choices are determined by a complex range of factors that we help our clients understand and influence, while always complying with the very highest ethical & professional standards.
SPECIFICALLY, OUR MARKET ACCESS HELPS COMPANIES AND ORGANIZATIONS TO:
go beyond understanding the formal pathways to access, to understand the underlying, unwritten rules and politics of access
based on this - develop compelling, locally relevant value stories and all necessary local evidence esp. around health economic benefits
advise on innovative commercial models that will work locally and support accelerated access, incl. PPP/tech transfers, discounting, cost sharing, risk sharing & value added services
build 'disruptive' outreach and engagement strategies, aimed at generating political and public support, incl. PAGs, KOLs, media and social/digital campaigning
develop integrated action plans, ensuring a fully joined-up approach between commercial, medical, regulatory, policy and communications teams
We do this in three ways:
targeted work around specific products, indications or technologies
working across a wider portfolio/franchise to develop an integrated approach to market access
providing corporate-level support to audit market access strategies and build internal capacity incl. toolkits & training